Läubli H - Search Results

1

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Adams OJ, Stanczak MA, von Gunten S, Läubli H. Adams OJ, et al. Among authors: laubli h. Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108. Glycobiology. 2018. PMID: 29309569 Free article. Review.

2

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A. Läubli H, et al. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15. Proc Natl Acad Sci U S A. 2014. PMID: 25225409 Free PMC article.

3

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Läubli H, Alisson-Silva F, Stanczak MA, Siddiqui SS, Deng L, Verhagen A, Varki N, Varki A. Läubli H, et al. J Biol Chem. 2014 Nov 28;289(48):33481-91. doi: 10.1074/jbc.M114.593129. Epub 2014 Oct 15. J Biol Chem. 2014. PMID: 25320078 Free PMC article.

4

Sialic acids in cancer biology and immunity.

Pearce OM, Läubli H. Pearce OM, et al. Among authors: laubli h. Glycobiology. 2016 Feb;26(2):111-28. doi: 10.1093/glycob/cwv097. Epub 2015 Oct 30. Glycobiology. 2016. PMID: 26518624 Review.

5

The immune system and cancer evasion strategies: therapeutic concepts.

Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. Muenst S, et al. Among authors: laubli h. J Intern Med. 2016 Jun;279(6):541-62. doi: 10.1111/joim.12470. Epub 2016 Jan 8. J Intern Med. 2016. PMID: 26748421 Free article. Review.

6

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F. Läubli H, et al. J Immunother Cancer. 2017 Jun 20;5:46. doi: 10.1186/s40425-017-0249-y. eCollection 2017. J Immunother Cancer. 2017. PMID: 28642817 Free PMC article.

7

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Läubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, Hertig A, Müller B, Gautschi O, Stenner F, Zippelius A, Egli A, Rothschild SI. Läubli H, et al. J Immunother Cancer. 2018 May 22;6(1):40. doi: 10.1186/s40425-018-0353-7. J Immunother Cancer. 2018. PMID: 29789020 Free PMC article.

8

Cancer Immunotherapy.

Pearce OMT, Läubli H. Pearce OMT, et al. Among authors: laubli h. Glycobiology. 2018 Sep 1;28(9):638-639. doi: 10.1093/glycob/cwy069. Glycobiology. 2018. PMID: 30084981 No abstract available.

9

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H. Stanczak MA, et al. Among authors: laubli h. J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24. J Clin Invest. 2018. PMID: 30130255 Free PMC article.

10

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H, Dirnhofer S, Zippelius A. Läubli H, et al. Virchows Arch. 2019 Apr;474(4):485-495. doi: 10.1007/s00428-018-2435-9. Epub 2018 Aug 25. Virchows Arch. 2019. PMID: 30143868

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page